NetworkNewsWire
Editorial Coverage: The field of precision medicine has latched
upon what may well be the Holy Grail in the fight against cancer.
When big data are utilized by teams of pathologists, data can be
incredibly helpful, but when the right data are comprehensively
analyzed by artificial intelligence (AI)-powered models, the data
can be downright lifesaving.
Predictive Oncology (NASDAQ: POAI) (POAI
Profile) is in an enviable position in the
precision-medicine industry due to its incredibly rich data set of
more than 150,000 clinically validated cases on its molecular
information platform, with 30,000-plus specific to ovarian cancer.
The company is leveraging this unique database through Artificial
Intelligence to provide the actionable insights needed to drive
pharma R&D programs and improve patient outcomes. A data asset
like this typically takes at least five years to fully validate and
most competitors are only in the early stages of the process.
Predictive Oncology already has it. The uniqueness of its data
combined with its proprietary AI platform show true disruptive
potential in the field of precision medicine. Leading pharma
companies in the space such as Roche Holding AG (OTCQX:
RHHBY), GlaxoSmithKline (NYSE: GSK),
AstraZeneca (NYSE: AZN) and Bristol-Myers
Squibb (NYSE: BMY) have also shown keen interest in the
promise of precision medicine and are making multibillion dollar
investments in the space.
- The precision medicine market is projected to explode to more
than $96 billion within the next five years.
- POAI has already assembled one of the largest databases of
drug-response and outcome data in the world.
- Helomics’ vast database of drug-response profiles
(response-ome) of 150,000 patient tumors spans 137 cancer
types.
To view an infographic of this editorial, click here.
Value of Data in Precision Medicine
For some time, clinicians have been utilizing key genomic data
to understand a patient’s individual tumor type in attempts to
effectively prescribe therapies that will work. However, the
scientific community has come to realize, due to low success rates
in these applications, that genomic data itself — utilizing a
just-genomics approach — doesn’t fully address the complexities of
cancer and is merely scratching the surface of personalized
medicine’s true potential.
The precision-medicine space has a real unmet need, with a
surging demand for a multi-omic approach rather than just genomics
to better understand and treat the complexities of cancer. The
multi-omic approach (genome, transcriptome, epigenome, proteome,
responseome and microbiome) provides researchers and clinicians the
comprehensive information and interactions necessary for new drug
development and treating each patient’s unique cancer in the most
effective method possible. Comparatively, the multi-omic approach
provides a three-dimensional, 360-degree view of the cancer, while
genomics alone is just a flat, one-dimensional image.
Market Potential
Major players in the space are looking to get their hands on
comprehensive, multi-omic data sets that can help them not only
understand the type of cancer a patient may have but also strongly
predict which therapies will be most effective in fighting each
specific cancer. Unfortunately, such data is fragmented and scarce,
and the initiation of such data collecting is costly and time
consuming. Predictive
Oncology (NASDAQ: POAI) has already assembled one of
the largest databases of drug-response and outcome data in the
world.
Indicating market trajectory, the precision medicine market is
projected to explode to more than $96 billion
within the next five years. The value of actionable data sets has
steadily increased across the pharma industry, as significant
acquisitions have commanded an ever-steeper price.
In January 2015, Swiss biopharma giant Roche paid $1 billion to
acquire a 57% stake in molecular information developer Foundation
Medicine, pledging another $157 million to accelerate product
development. Underscoring the importance of precision medicine and
the value of molecular information on cancers, Roche acquired the remainder of Foundation Medicine in
2018 for $2.4 billion, valuing the company at over $5.3 billion. At
the time of the acquisition, Foundation Medicine reported 68,000 cases on its molecular information
platform.
Predictive Assets
By comparison, Predictive Oncology (NASDAQ:
POAI) currently has about 150,000 cases on its molecular
information platform, with more than 30,000 specific to ovarian
cancer. The company’s data is highly differentiated, having both
drug-response data and access to historical outcome data from
patients. The value is evidenced in a joint collaborative agreement with UPMC/Magee.
The collaboration is focused on using D-CHIP(TM), an AI platform
from Helomics, a POAI subsidiary, to analyze the genomic and
drug-response profiles of women with ovarian cancer to determine
predictive value in terms of response/nonresponse to therapy. Both
parties believe that the collaboration will demonstrate the
enormous value of using AI-powered, evidence-based decision making
in the context of specific treatments on specific genotypes to
predict clinical outcomes for this group of patients.
With ovarian cancer as its first target, Helomics intends to
sequence 50% of its 30,000-plus ovarian tumors over the next nine
to twelve months, generating what may be the world’s first
comprehensive, actionable, multi-omic dataset for ovarian
cancer.
In addition to UPMC/Magee, Predictive Oncology has established
agreements with Interpace Diagnostics Group to build AI-driven
models of thyroid cancer to enhance diagnosis and identify the best
therapeutic options for thyroid cancer. The company also entered a
collaborative research agreement with molecular imaging company
ChemImage to establish the feasibility of coupling genomics to
Raman spectroscopy to better determine disease progression in
prostate cancer.
Helomics also participated in the landmark 100,000 Genomes Project, a UK-government project that
is sequencing whole genomes from National Health Service patients.
The project is focusing on rare and infectious diseases, along with
common types of cancer. The 100,00 Genomes Project featured nine
major pharmaceutical companies and only one molecular information
company — Predictive Oncology.
Standing Out
What sets Predictive Oncology apart in the quest for actionable
cancer intelligence is that PAOI’s data assets are already in
place, with data profiles dating back to 2003. By contrast,
companies beginning to collect and analyze data must wait to
discover how patients’ tumors will initially respond to prescribed
therapies and to evaluate patient outcomes, a process that takes
approximately five years. In short, POAI is on an execution
trajectory not a developmental plan. By coupling outcome data with
multi-omic data, POAI is creating what may be the most
comprehensive, actionable dataset on ovarian cancer in the world.
These actionable insights are imperative for pharmaceutical
research and development programs and, most importantly, improving
outcomes for the cancer patients of today and tomorrow.
Considering Roche’s $3.4 billion investment in Foundation
Medicine based on the value of its molecular information,
Predictive Oncology exhibits strong market potential. With a
current market capitalization of only about $14 million, there
should be an opportunity somewhere between here and the $3.4
billion Roche invested.
Today, Helomics’ vast database of drug-response profiles
(response-ome) of 150,000 patient tumors spans 137 cancer types—a
depth and breadth of data that many industry competitors only wish
they could obtain. When artificial intelligence is utilized in
predictive models to analyze this data, the model’s efficacy
becomes more fine-tuned in congruence with such a wealth of data.
Much like the search engines engineered by Google and Amazon, the
more information about a patient that is fed into a machine, the
better it is at predicting outcomes for that patient.
That’s the promise of precision medicine, being able to develop
drugs and tailor therapeutic treatments to each individual’s
specific cancer, providing the best possible outcomes. Predictive
Oncology is at the vanguard of delivering the actionable
intelligence required to bring the promise of precision medicine to
reality.
The race to develop actionable intelligence on tumors has begun,
and Predictive Oncology’s five-year head start has positioned it at
the head of the pack.
Pharma on the Hunt
Roche Holding AG (OTCQX: RHHBY), a global
pioneer in pharmaceuticals and diagnostics focused on advancing
science to improve people’s lives, has been developing medicines
with the goal of redefining treatment in oncology for over 50
years. The company’s efforts are still invested in innovative
treatments, including digital health software, which provides data-driven results to support life-changing
decisions. Roche uses artificial intelligence and algorithms to
deliver self-learning products that constantly update available
data and help healthcare professionals make more timely and
informed healthcare treatment decisions.
GlaxoSmithKline (NYSE: GSK), a science-led
global healthcare company, is focused on developing
transformational medicines to improve survival and potentially
achieve cures in the field of oncology. GSK recently announced its
collaboration with the University of California to establish a new
Laboratory for Genetics Research (LGR). This partnership aims to
accelerate the development of next-generation
functional genomics technologies and build on the databases GSK
currently has available from human genetics.
AstraZeneca (NYSE: AZN), a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialization of prescription medicines, is
utilizing precision medicine in the most prevalent and deadly tumor
types. AZN is concentrating on
biomarker-driven indications to dramatically improve five-year
survival in five tumor types, including ovarian cancer and
non-small cell lung cancer. Senior vice president of Precision
Medicine at AstraZeneca Ruth March notes that the greatest advance
of personalized healthcare in oncology has been the realization that some tumors are driven by individual
genes. Discovering which genes cause certain types of tumors
enables scientists to develop a medicine that’s best for that
tumor, and then select patients that are best for that
medicine.
Bristol-Myers Squibb (NYSE: BMY) is a global
biopharmaceutical company whose mission is to discover, develop and
deliver innovative medicines that help patients prevail over
serious diseases. BMY aims to create individualized treatment
strategies tailored to individual patients, offering the greatest
possible patient benefit. BMY is partnering with companies to
leverage next-generation sequencing to develop
gene expression profiles for immune-oncology assets studied across
a variety of cancers. BMY leadership sees this sequencing as a key
component of precision medicine; since each tumor has a different
biology, these biological differences can be associated with
different outcomes. The company continues to gain new insights
using sophisticated, proven and emerging technologies.
With very lives at stake, it’s little wonder that key players in
the pharma sector have shifted focus to precision medicine, a
powerhouse combination of rich, historical patient data and
powerful AI platforms.
For more information on Predictive Oncology,
visit Predictive
Oncology Inc. (NASDAQ: POAI)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to
reach all target markets, industries and demographics in the most
effective manner possible, (2) article and editorial syndication to
5,000+ news outlets (3), enhanced press release services to ensure
maximum impact, (4) social media distribution via the Investor
Brand Network (IBN) to nearly 2 million followers, (5) a full array
of corporate communications solutions, and (6) a total news
coverage solution with NNW Prime. As a
multifaceted organization with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience
of investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024